Dr Caroline Coats
- Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)
https://orcid.org/0000-0002-3208-470XPublications
2024
Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590) (PMID:39217447) (Early Online Publication)
Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13(5), e035993. (doi: 10.1161/JAHA.124.035993) (PMID:39056349)
Heywood, W. E. et al. (2024) A proof of principle 2D spatial proteome mapping analysis reveals distinct regional differences in the cardiac proteome. Life, 14(8), 970. (doi: 10.3390/life14080970) (PMID:39202712) (PMCID:PMC11355120)
Goldie, F. C. and Coats, C. J. (2024) New perspectives on early stage hypertrophic cardiomyopathy: measuring what matters. Circulation: Heart Failure, 17(8), e012093. (doi: 10.1161/CIRCHEARTFAILURE.124.012093) (PMID:39087345)
Maron, M. S. et al. (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 390(20), pp. 1849-1861. (doi: 10.1056/nejmoa2401424) (PMID:38739079)
Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832) (In Press)
Goldie, F. C., Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)
Veeratterapillay, K., Coats, C. J. , Martin, R., Chaudhry, B. and Coats, L. (2024) A case report of complex congenital heart disease co-existing with hypertrophic cardiomyopathy. European Heart Journal: Case Reports, 8(2), ytae038. (doi: 10.1093/ehjcr/ytae038) (PMID:38313326) (PMCID:PMC10836887)
Coats, C. J. et al. (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC: Heart Failure, 12(1), pp. 199-215. (doi: 10.1016/j.jchf.2023.10.004) (PMID:38032573)
2023
Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)
Owens, A. et al. (2023) Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure, 29(11), pp. 1576-1582. (doi: 10.1016/j.cardfail.2023.07.003) (PMID:37473912)
Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)
Moody, W. E. et al. (2023) British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Research and Practice, 10, 13. (doi: 10.1186/s44156-023-00028-7) (PMID:37653443) (PMCID:PMC10468878)
Bourke, J. et al. (2023) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 9(2), e001977. (doi: 10.1136/openhrt-2022-001977) (PMID:36252992) (PMCID:PMC9577913)
Topriceanu, C.-C. et al. (2023) The atrial and ventricular myocardial proteome of end-stage lamin heart disease. Acta Myologica, 42(2-3), pp. 43-52. (doi: 10.36185/2532-1900-339) (PMID:38090549) (PMCID:PMC10712656)
Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)
2022
Gillmore, J. D., Reilly, M. M., Coats, C. J. , Cooper, R., Cox, H., Coyne, M. R.E., Green, A. J., McGowan, R., Moody, W. E. and Hawkins, P. N. (2022) Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best Practice in Ireland and the UK. Advances in Therapy, 39(6), pp. 2292-2301. (doi: 10.1007/s12325-022-02139-9) (PMID:35419651) (PMCID:PMC9122857)
Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)
2018
Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)
Articles
Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590) (PMID:39217447) (Early Online Publication)
Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13(5), e035993. (doi: 10.1161/JAHA.124.035993) (PMID:39056349)
Heywood, W. E. et al. (2024) A proof of principle 2D spatial proteome mapping analysis reveals distinct regional differences in the cardiac proteome. Life, 14(8), 970. (doi: 10.3390/life14080970) (PMID:39202712) (PMCID:PMC11355120)
Goldie, F. C. and Coats, C. J. (2024) New perspectives on early stage hypertrophic cardiomyopathy: measuring what matters. Circulation: Heart Failure, 17(8), e012093. (doi: 10.1161/CIRCHEARTFAILURE.124.012093) (PMID:39087345)
Maron, M. S. et al. (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 390(20), pp. 1849-1861. (doi: 10.1056/nejmoa2401424) (PMID:38739079)
Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832) (In Press)
Goldie, F. C., Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)
Veeratterapillay, K., Coats, C. J. , Martin, R., Chaudhry, B. and Coats, L. (2024) A case report of complex congenital heart disease co-existing with hypertrophic cardiomyopathy. European Heart Journal: Case Reports, 8(2), ytae038. (doi: 10.1093/ehjcr/ytae038) (PMID:38313326) (PMCID:PMC10836887)
Coats, C. J. et al. (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC: Heart Failure, 12(1), pp. 199-215. (doi: 10.1016/j.jchf.2023.10.004) (PMID:38032573)
Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)
Owens, A. et al. (2023) Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving Disopyramide: REDWOOD-HCM Cohort 3. Journal of Cardiac Failure, 29(11), pp. 1576-1582. (doi: 10.1016/j.cardfail.2023.07.003) (PMID:37473912)
Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)
Moody, W. E. et al. (2023) British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis. Echo Research and Practice, 10, 13. (doi: 10.1186/s44156-023-00028-7) (PMID:37653443) (PMCID:PMC10468878)
Bourke, J. et al. (2023) Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 9(2), e001977. (doi: 10.1136/openhrt-2022-001977) (PMID:36252992) (PMCID:PMC9577913)
Topriceanu, C.-C. et al. (2023) The atrial and ventricular myocardial proteome of end-stage lamin heart disease. Acta Myologica, 42(2-3), pp. 43-52. (doi: 10.36185/2532-1900-339) (PMID:38090549) (PMCID:PMC10712656)
Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)
Gillmore, J. D., Reilly, M. M., Coats, C. J. , Cooper, R., Cox, H., Coyne, M. R.E., Green, A. J., McGowan, R., Moody, W. E. and Hawkins, P. N. (2022) Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best Practice in Ireland and the UK. Advances in Therapy, 39(6), pp. 2292-2301. (doi: 10.1007/s12325-022-02139-9) (PMID:35419651) (PMCID:PMC9122857)
Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)
Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)